These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28597906)

  • 1. Platelet receptors as therapeutic targets: Past, present and future.
    Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W
    Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.
    De Meyer SF; Vanhoorelbeke K; Ulrichts H; Staelens S; Feys HB; Salles I; Fontayne A; Deckmyn H
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):191-207. PubMed ID: 17017902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents.
    Goto S
    Curr Vasc Pharmacol; 2004 Jan; 2(1):23-32. PubMed ID: 15320830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine.
    Chen Y; Ju LA
    Stroke Vasc Neurol; 2020 Jun; 5(2):185-197. PubMed ID: 32606086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-glycoprotein Ib causes platelet aggregation: different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer.
    O'Brien JR; Etherington MD
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):453-61. PubMed ID: 9818994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of platelet glycoprotein Ib and its antithrombotic potential.
    Vanhoorelbeke K; Ulrichts H; Van de Walle G; Fontayne A; Deckmyn H
    Curr Pharm Des; 2007; 13(26):2684-97. PubMed ID: 17897012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic peripheral arterial occlusive disease, platelet glycoproteins GPIIb-IIIa and GP Ib-IX, plasma von Willebrand factor and plasma fibrinogen concentrations in patients with type 2 diabetes mellitus].
    Gosk-Bierska I; Adamiec R; Doskocz W; Ciosek W
    Pol Arch Med Wewn; 2000; 103(3-4):139-45. PubMed ID: 11236240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
    Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelets and primary haemostasis.
    Clemetson KJ
    Thromb Res; 2012 Mar; 129(3):220-4. PubMed ID: 22178577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.
    Ferguson JJ; Zaqqa M
    Drugs; 1999 Dec; 58(6):965-82. PubMed ID: 10651385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents.
    Goto S
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Apr; 2(2):149-56. PubMed ID: 15320797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.
    Ward CM; Andrews RK; Smith AI; Berndt MC
    Biochemistry; 1996 Apr; 35(15):4929-38. PubMed ID: 8664285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives in antiplatelet therapy.
    Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
    Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet drugs. A comparative review.
    Schrör K
    Drugs; 1995 Jul; 50(1):7-28. PubMed ID: 7588091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.